Title:
NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF
Document Type and Number:
WIPO Patent Application WO/2011/102577
Kind Code:
A1
Abstract:
The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of side effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system.
Inventors:
PARK TAE SUN (KR)
KIM HA WON (KR)
HWANG WAN KYUN (KR)
KIM HA WON (KR)
HWANG WAN KYUN (KR)
Application Number:
PCT/KR2010/005423
Publication Date:
August 25, 2011
Filing Date:
August 17, 2010
Export Citation:
Assignee:
UNIV YONSEI IACF (KR)
PARK TAE SUN (KR)
KIM HA WON (KR)
HWANG WAN KYUN (KR)
PARK TAE SUN (KR)
KIM HA WON (KR)
HWANG WAN KYUN (KR)
International Classes:
A61K31/37; A61P3/00; A61P3/04; A61P3/10
Foreign References:
| KR20010001270A | 2001-01-05 |
Other References:
WU Q. ET AL.: "Bioactivity guided isolation of alpha-glucosidase inhibitor from whole herbs of Crossostephium chinense.", ZNONGGUO ZHONG YAO ZAZHI., vol. 34, no. 17, September 2009 (2009-09-01), pages 2206 - 2211
Attorney, Agent or Firm:
DANA PATENT LAW FIRM (KR)
특허법인 다나 (KR)
특허법인 다나 (KR)
Download PDF:
Claims:
Previous Patent: ABNORMALITY DIAGNOSIS DEVICE AND METHOD OF CELL BALANCING CIRCUIT
Next Patent: SPINE CORRECTING WHEEL-BACK DEVICE
Next Patent: SPINE CORRECTING WHEEL-BACK DEVICE